Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
50%
Ph phase_3
1
25%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (66.7%)
Phase 31 (33.3%)

Trials by Status

recruiting125%
unknown125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351
completedphase_1

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

NCT06935266
completedphase_1

A Study of TAK-881 and HyQvia in Healthy Adults

NCT06895967
unknown

Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA

NCT06955793

Clinical Trials (4)

Showing 4 of 4 trials
NCT06747351Phase 3

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Recruiting
NCT06935266Phase 1

A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

Completed
NCT06895967Phase 1

A Study of TAK-881 and HyQvia in Healthy Adults

Completed
NCT06955793

Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4